TCIM
COGT icon

TIAA CREF Investment Management’s Cogent Biosciences COGT Stock Holding History

TIAA CREF Investment Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$122K Buy
6,945
+988
+17% +$16.9K ﹤0.01% 2944
2018
Q4 		$105K Buy
+5,957
New +$176K ﹤0.01% 2957

Other funds holding COGT

AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TIAA CREF Investment Management's COGT Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Cogent Biosciences (COGT) stake by 17% in Q1 2019, buying an estimated $16.9K and bringing the position to 6,945 shares worth $122K. The position accounts for ﹤0.01% of the portfolio, ranked #2944.

TIAA CREF Investment Management first reported a position in COGT in Q4 2018 and has held it in 2 quarters since. 53 funds tracked by Wall St. Rank hold COGT as of Q1 2019.

  • TIAA CREF Investment Management held 6,945 shares of Cogent Biosciences worth $122K as of Q1 2019.
  • TIAA CREF Investment Management bought 988 Cogent Biosciences shares in Q1 2019, an estimated $16.9K.
  • Cogent Biosciences made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2944 holding.
  • TIAA CREF Investment Management first reported a position in Cogent Biosciences in Q4 2018 and has held it in 2 quarters since.
  • 53 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.